Asset Details
Do you wish to reserve the book?
Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity — 27 month follow-up results from Turkey
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity — 27 month follow-up results from Turkey
Do you wish to request the book?
Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity — 27 month follow-up results from Turkey
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity — 27 month follow-up results from Turkey
2015
Overview
Purpose
To study the efficacy of intravitreal bevacizumab (IVB) injection as a single treatment for retinopathy of prematurity (ROP).
Methods
This was a prospective interventional case series study performed in a clinical practice setting; a total of 122 patients including prethreshold (type 1) (
n
= 79, 152 eyes, six unilateral), threshold (
n
= 12, 24 eyes), and aggressive posterior (APROP) (
n
= 31, 62 eyes); cases were included without any randomization or masking. A total of 253 IVB injections, 238 in the first session, 11 in the second session, and four in the third session were performed, and followed up for a mean of 89.155 ± 4.277 (range 82 to 105) weeks of postmenstrual age (PMA). Regression of ROP, maturation of the retina, and associated complications were evaluated.
Results
Total regression was achieved in 227/238 eyes (95.4 %) after the first dose injection. The remaining 11 received a second injection, after which an additional seven (234/238; 98.2 %) regressed; after the third injection, the remaining 4 (238/238; 100 %) regressed. Complete retinal vascular maturation was achieved without any significant complications in all of the cases.
Conclusions
IVB injection as monotherapy seems to be a very effective treatment modality for ROP. Based on timely intervention, IVB as a single treatment modality can salvage almost all ROP cases before stage 4.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
Angiogenesis Inhibitors - therapeutic use
/ Bevacizumab - therapeutic use
/ Humans
/ Infant
/ Medicine
/ Retinopathy of Prematurity - classification
/ Retinopathy of Prematurity - diagnosis
/ Retinopathy of Prematurity - drug therapy
/ Turkey
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
